Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1881 Target Snapshot

Prostaglandin E2 receptor EP2 subtype · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,236Compounds
215Assays
8Approved Drugs
1,340.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Prostaglandin E2 receptor EP2 subtype shows approved-linked disease relevance led by cardiovascular disease. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P43116. Start with cardiovascular disease, then reuse UniProt P43116 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with cardiovascular disease, then reuse UniProt P43116 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
cardiovascular disease

Prostaglandin E2 receptor EP2 subtype shows approved-linked disease relevance led by cardiovascular disease. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with cardiovascular disease because it currently carries approved-linked support. Linked drugs include ALPROSTADIL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Prostaglandin E2 receptor EP2 subtype as ChEMBL target CHEMBL1881, mapped to UniProt P43116. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Prostaglandin E2 receptor EP2 subtype
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1881
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P43116
Prostaglandin E2 receptor EP2 subtype
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Prostaglandin E2 receptor EP2 subtype is the right protein anchor across sources, using UniProt P43116 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why cardiovascular disease is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameProstaglandin E2 receptor EP2 subtype
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP43116
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelProstaglandin E2 receptor EP2 subtype
UniProt AccessionP43116
Component TypeProtein
Sequence Length358 aa

Prostaglandin E2 receptor EP2 subtype

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Prostaglandin E2 receptor EP2 subtype, mapped to UniProt P43116. Sequence length is 358 aa.

Mapped IDP43116
Review nameProstaglandin E2 receptor EP2 subtype
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Prostaglandin E2 receptor EP2 subtype shows approved-linked disease relevance led by cardiovascular disease. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
cardiovascular disease
1 linked drug · 1 direct · 1 efficacy
Linked drugALPROSTADIL
Approved-linked Approved
erectile dysfunction
1 linked drug · 1 direct · 1 efficacy
Linked drugALPROSTADIL
Approved-linked Approved
ocular hypertension
1 linked drug · 1 direct · 1 efficacy
Linked drugOMIDENEPAG ISOPROPYL
Approved-linked Approved
open-angle glaucoma
1 linked drug · 1 direct · 1 efficacy
Linked drugOMIDENEPAG ISOPROPYL
Approved-linked Approved
Patent ductus arteriosus
1 linked drug · 1 direct · 1 efficacy
Linked drugALPROSTADIL
Late clinical Phase III
glaucoma
2 linked drugs · 2 direct · 2 efficacy
Linked drugOMIDENEPAG
Linked drugOMIDENEPAG ISOPROPYL
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with cardiovascular disease because it currently carries approved-linked support. Linked drugs include ALPROSTADIL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasecardiovascular disease
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

8
Approved
2
Phase III
13
Phase II
3
Phase I
Assay Mix

Activity Type Distribution

IC50267.0
KI537.0
EC50529.0
KD7.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4217198 10.17 EC50 0.068 Preclinical
CHEMBL4204996 10.07 EC50 0.086 Preclinical
CHEMBL3794302 9.96 EC50 0.11 Preclinical
CHEMBL4205480 9.96 EC50 0.11 Preclinical
CHEMBL3793515 9.85 EC50 0.14 Preclinical
CHEMBL3971632 9.82 EC50 0.15 Preclinical
CHEMBL3977724 9.82 EC50 0.15 Preclinical
CHEMBL3794016 9.77 EC50 0.17 Preclinical
CHEMBL3793862 9.7 EC50 0.2 Preclinical
CHEMBL3792632 9.68 EC50 0.21 Preclinical
Distribution

pChEMBL Value Distribution

131
5.0
147
5.5
113
6.0
85
6.5
73
7.0
97
7.5
90
8.0
73
8.5
30
9.0
10
9.5
pChEMBL
Approved Drugs

Approved Drugs

OMIDENEPAG ISOPROPYL
CHEMBL4297666
Approved 2022
Properties Compare Identifier
TREPROSTINIL
CHEMBL1237119
Approved 2002
Properties Compare Identifier
DINOPROSTONE
CHEMBL548
Approved 1977
Properties Compare Identifier
LAROPIPRANT
CHEMBL426559
Properties Compare Identifier
Assay Landscape

Assay Landscape

215
Total Assays
469
Tested Compounds
2
Assay Types
Binding — 160 assays, 469 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 94 178 6.0
cell-based format 53 202 6.3
assay format 4 40 7.1
cell membrane format 3 38 8.7
cell-free format 3 11 5.8
tissue-based format 3 0 —
Functional — 55 assays, 298 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 44 275 7.2
assay format 7 16 6.3
single protein format 3 3 6.2
tissue-based format 1 4 6.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine